Suchen Sie nach Informationen zu Actavis US-Zentrale? Folgen Sie den Links unten, um alle Informationen zu finden, die Sie benötigen, und mehr.
https://en.wikipedia.org/wiki/Actavis
https://sunrisehouse.com/research/pharmaceutical-industry/actavis-inc/
Hydrocodone is classified as a Schedule II controlled substance by the United States Drug Enforcement Administration (DEA). Ozurdex (dexamethasone) is used to treat hypertension. Generic forms of the opiate drug oxycodone were marketed by Actavis, Inc. These included oxycodone (OxyContin) and a generic form of acetaminophen and oxycodone ...
https://www.actavis.co.id/our-products/
Patient safety is our focus. Patient safety is at the heart of all we do. All of our products undergo thorough safety monitoring and evaluation processes …
https://opengovus.com/sam-entity/099262404
ACTAVIS US (DUNS #099262404) is an entity registered with System for Award Management (SAM). The business registration date is August 3, 2004. The address is 200 Elmora Ave, Elizabeth, NJ 07202-1106.
https://www.tevapharm.com/news-and-media/latest-news/teva-completes-acquisition-of-actavis-generics/
“The acquisition of Actavis Generics comes at a time when Teva is stronger than ever—in both our generics and specialty businesses,” said Erez Vigodman, President and CEO, Teva. ... United States, 215-591-8912 Ran Meir, United States, 215-591-3033 Tomer Amitai, Israel, 972 (3) 926-7656 or
https://www.ftc.gov/legal-library/browse/cases-proceedings/1210132-watson-pharmaceuticals-actavis-inc-matter
The FTC required Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive. The …
Wir hoffen, dass Sie über die obigen Links alle notwendigen Informationen zu Actavis US-Zentrale gefunden haben.
